跳至主要内容
临床试验/NCT02403024
NCT02403024已完成不适用

I-Walk-CRC - Feasibility and Efficacy of Interval Walking in Patients With Colorectal Cancer

Rigshospitalet, Denmark4 个研究点 分布在 1 个国家目标入组 39 人开始时间: 2015年8月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
39
试验地点
4
主要终点
Change in VO2peak

研究概览

简要总结

Background: The level physical exercise is strongly associated with colorectal cancer risk in the general population, and recent data shows that physical activity after a colorectal cancer diagnosis is inversely associated with mortality risk, indication the physical exercise can protect against disease progression. However, few studies have successfully performed exercise interventions in patients with colorectal cancer, and the potential mechanisms responsible for the tumor suppressing effects of exercise remain poorly explored.

Purpose: To investigate interval-walking, delivered by the InterWalk smart phone application as exercise-modality in patients with colorectal cancer. Specifically it is the aim to explore if InterWalk is safe and feasible as well as effective to improve cardio-metabolic health profile.

Subjects: Colorectal cancer patients, stage I-III, who are at least one month post-surgery and have concluded any adjuvant chemotherapy treatment, are eligible for inclusion. Exclusion criteria are: age <18; any major surgical procedure planned within 6 months after inclusion; pregnancy; ongoing treatment for any known malignancy; performance status > 1; unable to read and understand Danish

Methods: 40 colorectal cancer patients are included and randomized to I) InterWalk or II) waiting list control for 24 weeks. Patients are evaluated at baseline, week 12 and week 24 by assessment measures to determine cardio-metabolic health profile and other relevant study outcomes, including: cardiopulmonary exercise test (VO2peak); anthropometrics; blood pressure; resting heart rate; body composition; health related quality of life questionnaires; plasma concentration levels of cholesterol, triglycerides, insulin, glucose and inflammatory cytokines; insulin sensitivity; and cognitive function.

详细描述

INTRODUCTION More than 30.000 individuals are living with a colorectal cancer (CRC) diagnosis in Denmark today. Due to marked advances in surgical and medical treatment, as well as novel screening programs, this number is expected to increase over the coming years. Numerous studies have shown that physical activity is inversely associated with colorectal cancer risk. A meta-analysis of 52 studies found that regular participation in physical activity reduced disease risk by 24% (HR: 0.76 , 95%Confidence Interval [95%CI]: 0.72 - 0.81). Recent evidence furthermore shows that physical activity after a CRC diagnosis is a strong independent predictor for overall survival, CRC-specific survival, and survival after disease relapse. CRC patients who adhere to the current recommendation of at least 150 min moderate intensity physical activity per week have an estimated 10-40% lower CRC-specific and 20-50% lower overall mortality risk in comparison to sedentary counterparts. The causative mechanisms responsible for this protective effect are not fully elucidated, but several studies have shown that metabolic health factors, i.e. overweight/adiposity, systemic levels of glucose, insulin, Insulin-like Growth Factor (IGF)-1, leptin, adiponectin and inflammatory cytokines (TNF-α, CRP) are associated with CRC prognosis. These factors are, under normal circumstances modifiable through physical activity and exercise, which may constitute a plausible mode of action, through which, exercise may reduce risk of disease progression as well as development and/or progression of cardio-metabolic co-morbid disorders.

BACKGROUND Over the last decade, more than 70 studies have explored the capacity of physical exercise to improve physiological (fitness, muscle strength, body composition) and psychosocial (fatigue, depression, emotional well-being) outcomes in patients with cancer during and after anti-neoplastic therapy and although CRC is among the most prevalent malignancies, few exercise-trials have been performed in this patient group. The reason for this notable low number of studies, relative to other common cancers in particular breast and prostate cancer, may be a number of disease and treatment specific phenomena, e.g. high prevalence of co-morbidities, stoma, late-effects from surgery or adjuvants therapies etc., which may complicate participation in traditional hospital-based exercise-programs, which is often comprised of fitness- and strength-training. A recent meta-analysis included just 3 randomized trials investigating exercise in CRC patients, and found positive effects exercise vs control on cardiovascular fitness; standardized mean difference: 0.59 [95%CI 0.25-0.93], P<0.01. A recent pilot study furthermore showed that home-based exercise improved several metabolic factors including reduction in body weight, plasma insulin levels and improved insulin sensitivity. Thus, these data indicate that CRC patients can improve cardio-metabolic health profile by physical exercise; however, the present body of research have included a total of less than 200 patients; explored various exercise-modalities, and applied inconsistent and/or indirect assessment-methods. To this end, there is a remaining need for high quality evidence describing effective exercise-interventions in CRC patients, particularly interventions aimed to be successfully implemented in clinical practice in case of positive results.

Interval training, as characterized by inter-changing cycles of high and low intensity exercise, have long been recognized as the most effective exercise-modality to improve cardiopulmonary fitness, and can furthermore induce equal or greater metabolic effects than continuous exercise over longer duration. Considerable challenges exists however, when performing high intensity interval exercise-training in clinical settings. This type of exercise often needs to be performed on ergometer bicycles or treadmills and organized as supervised, hospital-based training to ensure proper monitoring and feedback to participants for optimal exercise intensity and progression, which limits the dissemination potential beyond the trial period.

Center for Physical Activity Research (CFAS) have performed a number of trials showing that interval training can be performed as free-living interval-walking, consisting of repeating cycles of 3 minutes fast walking followed by 3 minutes slow walking with significant positive effects in cardio-metabolic health profile. Our studies show, that 16 weeks of interval-walking improved VO2peak (+4ml /kg/min) reduced bodyweight (-4 kg) and fat mass (-3 kg) in patients with type 2 diabetes. Moreover, interval-walking improved plasma lipid-profile, glucose metabolism and insulin sensitivity, in contrast to continuous walking, which was matched for training-volume and energy expenditure. In parallel with these intervention-studies, a smart-phone application, called InterWalk (www.InterWalk.dk), has been developed, which can deliver this training program of repeating cycles: 3 minutes fast walking followed by 3 minutes slow walking. The exercise-program is based on an individualized test-function with live-feedback, ensuring proper exercise-intensities (walking-speed), and can simultaneously store test- and training data (exercise-time, walking-speed, distance etc.) to an external server for research purposes. Preliminary data shows that three months home-based interval-walking using the InterWalk-application can improve fitness by ~10%. Thus, our preliminary data shows InterWalk can deliver an un-supervised, yet individualized, structured and objectively monitored exercise-program which can effectively improve cardio-metabolic health, and may be more applicable and feasible, compared to traditional hospital-based programs in stigmatized patient groups with major co-morbid complications.

The investigators therefore propose this intervention can have a great health promoting potential in patients with CRC; however previous work have found considerable barriers and complications associated with successful participation in exercise-programs for this patient group. Thus, the investigators intend to explore whether interval-walking, delivered by the InterWalk-app, is safe and feasible, and furthermore the investigatorsintend to explore if the intervention can cause similar positive effects as the investigators have seen previously in other clinical populations.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with a verified stage I-III CRC diagnosis who has
  • All surgical and oncological treatments must be terminated

排除标准

  • Any major surgical procedure planned within 6 months after inclusion
  • Pregnancy
  • Ongoing treatment for any known current malignancy
  • Performance status > 1
  • Inability to read and understand Danish
  • Physically active for more than 150 minutes (moderate intensity) per week thus adhering to the current recommendations

研究组 & 干预措施

InterWalk

Experimental

The intervention program will prescribe that patients performing 150 min of interval training per week.

干预措施: InterWalk (Behavioral)

Waiting list Control

Other

Patients allocated to the waiting-list control group will receive usual care control for the first 12 weeks of the study and will receive the same instructions for download and use of the InterWalk app in the final 12 weeks.

干预措施: Waiting list control (Behavioral)

结局指标

主要结局

Change in VO2peak

时间窗: Baseline to week 12

On a stationary bicycle, the participants perform 3 minutes warm up on 70 Watt followed by a step-by-step incremental test with workload increasing by 20 Watt every minute until exhaustion with direct measurement of oxygen uptake and carbon dioxide excretion with gas-exchange online-measurement equipment (Cosmed Quark, Rome, Italy).

次要结局

  • Change in Body composition(Baseline-to-week 12; baseline-to-week 24; week 12-to-week 24)
  • Changes in bloodbiochemistry from fasting blood samples(Baseline-to-week 12; baseline-to-week 24; week 12-to-week 24)
  • Changes in patient-reported Quality of Life(Baseline-to-week 12; baseline-to-week 24; week 12-to-week 24)
  • Changes in insulin sensityvity by measure of Oral Glucose Tolerance Test (OGTT)(Baseline-to-week 12; baseline-to-week 24; week 12-to-week 24)
  • Change in VO2peak (secondary comparisons)(baseline-to-week24, week 12-to-week 24)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jesper Frank Christensen, PhD

Post doc

Rigshospitalet, Denmark

研究点 (4)

Loading locations...

相似试验